Editor-in-Chief

Sagar Lonial, MD, FACP

Editor-in-Chief

Sagar Lonial, MD, FACP, is Chair and Professor in the Department of Hematology and Medical Oncology, the Anne and Bernard Gray Family Chair in Cancer, and Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine in Atlanta, Georgia.

Dr. Lonial, who has authored or coauthored more than 200 peer-reviewed publications, is “internationally recognized as a leading authority in multiple myeloma treatment and research,” according to his biography from the Winship Cancer Institute.

He is a member of the Society of Hematologic Oncology (SOHO) Board of Directors and Chair of the SOHO Education Committee. Dr. Lonial is also involved with numerous other professional organizations.

Articles by Sagar Lonial, MD, FACP

Sagar Lonial, MD, FACPVideo Insights | September 19, 2023
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
View More
Sagar Lonial, MD, FACPPrint | August 17, 2023
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Sagar Lonial, MD, FACPMeeting News | June 9, 2023
Dr. Lonial shares his top highlights in multiple myeloma from the EHA and ASCO meetings.
Sagar Lonial, MD, FACPViewpoints | May 12, 2023
To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”
Thomas Martin, MDVideo Insights | May 2, 2023
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
Thomas Martin, MDVideo Insights | May 2, 2023
The panel discusses side effect management with CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 1, 2023
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Thomas Martin, MDVideo Insights | May 1, 2023
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel addresses the potential for frontline CAR-T use.
Thomas Martin, MDVideo Insights | April 28, 2023
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
Thomas Martin, MDVideo Insights | April 27, 2023
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Thomas Martin, MDVideo Insights | April 27, 2023
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
Thomas Martin, MDVideo Insights | April 26, 2023
BCMA-targeted autologous CAR T-cell therapies are discussed.
Thomas Martin, MDVideo Insights | April 26, 2023
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Thomas Martin, MDVideo Insights | April 25, 2023
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
Thomas Martin, MDVideo Insights | April 24, 2023
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
Sagar Lonial, MD, FACPMyeloma | March 6, 2023
Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.
Sagar Lonial, MD, FACPPrint | December 22, 2022
The past few years have been more than a challenge for those of us in health care, but we have learned many lessons.
Chadi Nabhan, MD, MBA, FACPMyeloma | December 14, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more.
Sagar Lonial, MD, FACPPrint | June 23, 2022
ASCO, EHA, and other medical society meetings represent the best of who we are—people working together toward a common ...